vs

Side-by-side financial comparison of Lionsgate Studios Corp. (LION) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Lionsgate Studios Corp. is the larger business by last-quarter revenue ($724.3M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -6.4%, a 40.8% gap on every dollar of revenue. On growth, Lionsgate Studios Corp. posted the faster year-over-year revenue change (52.5% vs 4.8%).

Lionsgate Canada is a Canadian entertainment company and a subsidiary of Lionsgate Studios. Based in the Entertainment District in the city of Toronto, the company is primarily involved in the acquisition and production of films and television series.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

LION vs RPRX — Head-to-Head

Bigger by revenue
LION
LION
1.2× larger
LION
$724.3M
$622.0M
RPRX
Growing faster (revenue YoY)
LION
LION
+47.7% gap
LION
52.5%
4.8%
RPRX
Higher net margin
RPRX
RPRX
40.8% more per $
RPRX
34.4%
-6.4%
LION

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
LION
LION
RPRX
RPRX
Revenue
$724.3M
$622.0M
Net Profit
$-46.2M
$214.2M
Gross Margin
Operating Margin
5.0%
62.4%
Net Margin
-6.4%
34.4%
Revenue YoY
52.5%
4.8%
Net Profit YoY
59.3%
2.9%
EPS (diluted)
$-0.16
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LION
LION
RPRX
RPRX
Q4 25
$724.3M
$622.0M
Q3 25
$475.1M
$609.3M
Q2 25
$525.9M
$578.7M
Q1 25
$568.2M
Q4 24
$593.6M
Q3 24
$564.7M
Q2 24
$537.3M
Q1 24
$568.0M
Net Profit
LION
LION
RPRX
RPRX
Q4 25
$-46.2M
$214.2M
Q3 25
$-113.5M
$288.2M
Q2 25
$-108.9M
$30.2M
Q1 25
$238.3M
Q4 24
$208.2M
Q3 24
$544.0M
Q2 24
$102.0M
Q1 24
$4.8M
Operating Margin
LION
LION
RPRX
RPRX
Q4 25
5.0%
62.4%
Q3 25
-9.7%
70.1%
Q2 25
-2.0%
36.3%
Q1 25
94.0%
Q4 24
60.9%
Q3 24
Q2 24
50.2%
Q1 24
-13.0%
Net Margin
LION
LION
RPRX
RPRX
Q4 25
-6.4%
34.4%
Q3 25
-23.9%
47.3%
Q2 25
-20.7%
5.2%
Q1 25
41.9%
Q4 24
35.1%
Q3 24
96.3%
Q2 24
19.0%
Q1 24
0.8%
EPS (diluted)
LION
LION
RPRX
RPRX
Q4 25
$-0.16
$0.49
Q3 25
$-0.39
$0.67
Q2 25
$-0.40
$0.07
Q1 25
$0.55
Q4 24
$0.46
Q3 24
$1.21
Q2 24
$0.23
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LION
LION
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$182.4M
$618.7M
Total DebtLower is stronger
$1.8B
$9.0B
Stockholders' EquityBook value
$-1.3B
$9.7B
Total Assets
$5.2B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LION
LION
RPRX
RPRX
Q4 25
$182.4M
$618.7M
Q3 25
$202.4M
$938.9M
Q2 25
$186.1M
$631.9M
Q1 25
$1.1B
Q4 24
$929.0M
Q3 24
$950.1M
Q2 24
$1.8B
Q1 24
$843.0M
Total Debt
LION
LION
RPRX
RPRX
Q4 25
$1.8B
$9.0B
Q3 25
$1.8B
$8.9B
Q2 25
$1.5B
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
LION
LION
RPRX
RPRX
Q4 25
$-1.3B
$9.7B
Q3 25
$-1.3B
$9.6B
Q2 25
$-1.1B
$9.5B
Q1 25
$9.8B
Q4 24
$10.3B
Q3 24
$10.3B
Q2 24
$9.8B
Q1 24
$9.9B
Total Assets
LION
LION
RPRX
RPRX
Q4 25
$5.2B
$19.6B
Q3 25
$5.2B
$19.3B
Q2 25
$5.2B
$18.3B
Q1 25
$17.6B
Q4 24
$18.2B
Q3 24
$18.0B
Q2 24
$17.7B
Q1 24
$16.1B
Debt / Equity
LION
LION
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LION
LION
RPRX
RPRX
Operating Cash FlowLast quarter
$-108.9M
$827.1M
Free Cash FlowOCF − Capex
$-111.9M
FCF MarginFCF / Revenue
-15.4%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LION
LION
RPRX
RPRX
Q4 25
$-108.9M
$827.1M
Q3 25
$-104.0M
$702.6M
Q2 25
$-31.0M
$364.0M
Q1 25
$596.1M
Q4 24
$742.5M
Q3 24
$703.6M
Q2 24
$658.2M
Q1 24
$664.6M
Free Cash Flow
LION
LION
RPRX
RPRX
Q4 25
$-111.9M
Q3 25
$-107.2M
Q2 25
$-34.5M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
LION
LION
RPRX
RPRX
Q4 25
-15.4%
Q3 25
-22.6%
Q2 25
-6.6%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
LION
LION
RPRX
RPRX
Q4 25
0.4%
Q3 25
0.7%
Q2 25
0.7%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
LION
LION
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LION
LION

Television Production$303.1M42%
Digital Media$155.1M21%
Third Party Purchasers Individual Agreements$91.2M13%
Theatrical$70.7M10%
Domestic Television$43.1M6%
Starz Business$24.1M3%
Other Media$17.6M2%
Packaged Media$14.1M2%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons